The initial success of Sildenafil undeniably reshaped the medication landscape, but betting in companies strongly reliant on unbranded versions presents a uncertain picture. Although early earnings were impressive, the cessation of patents and the appearance of discounted alternatives have weakened market share. Consequently, a thorough evaluation